Journal scan

Cardio drug could reduce chemotherapy effect on children’s hearts

A cardioprotective drug could help prevent long-term heart damage in children who receive chemotherapy, say researchers in the United States.
Cardioprotective drug can reduce chemotherapy effect on children's hearts

A cardioprotective drug could help prevent long-term heart damage in children who receive chemotherapy, say researchers in the United States.

When the team reviewed the medical literature, they found that anthracyclines – among the most commonly used chemotherapeutic drugs for children with cancer – are effective but increase the risk of damaging the heart.

They also found that the cardioprotective agent dexrazoxane can prevent many of the toxic effects of chemotherapy treatment, without reducing the anti-cancer effect.

Wayne State University School of Medicine and the Children’s Hospital of Michigan lead study author Steven Lipshultz says the review: 'defines that the price of treatment for childhood cancer for many survivors is persistent, often progressive, and pervasive cardiotoxicity for those treated with anthracycline chemotherapy,’

‘This can be ameliorated or

...

Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Nursing Standard
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?

Jobs